Log in

NASDAQ:XOMAXOMA Stock Price, Forecast & News

$19.08
-0.14 (-0.73 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.50
Now: $19.08
$19.22
50-Day Range
$19.21
MA: $21.34
$23.30
52-Week Range
$14.14
Now: $19.08
$28.85
Volume50,500 shs
Average Volume93,957 shs
Market Capitalization$210.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More
XOMA logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.37 million
Book Value$5.03 per share

Profitability

Net Income$-1,980,000.00
Net Margins-102.32%

Miscellaneous

Employees11
Market Cap$210.26 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA (NASDAQ:XOMA) Frequently Asked Questions

How has XOMA's stock been impacted by COVID-19 (Coronavirus)?

XOMA's stock was trading at $19.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have decreased by 2.2% and is now trading at $19.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) issued its earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.33. The biotechnology company had revenue of $0.80 million for the quarter, compared to analyst estimates of $3.40 million. XOMA had a negative return on equity of 34.27% and a negative net margin of 102.32%. View XOMA's earnings history.

What price target have analysts set for XOMA?

2 brokerages have issued 1-year target prices for XOMA's shares. Their forecasts range from $29.00 to $30.00. On average, they expect XOMA's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View analysts' price targets for XOMA.

Has XOMA been receiving favorable news coverage?

Press coverage about XOMA stock has been trending neutral on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about XOMA.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $19.08.

How big of a company is XOMA?

XOMA has a market capitalization of $210.26 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.